Abstracts from the 2023 American Cough Conference
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:201 |
---|---|
Enthalten in: |
Lung - 201(2023), Suppl 1 vom: Aug., Seite 1-6 |
Sprache: |
Englisch |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
Themen: |
Camlipixant |
---|
Anmerkungen: |
© Springer Science+Business Media, LLC, part of Springer Nature 2023 |
---|
doi: |
10.1007/s00408-023-00634-6 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
OLC2144958920 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | OLC2144958920 | ||
003 | DE-627 | ||
005 | 20240118101954.0 | ||
007 | tu | ||
008 | 240118s2023 xx ||||| 00| ||eng c | ||
024 | 7 | |a 10.1007/s00408-023-00634-6 |2 doi | |
035 | |a (DE-627)OLC2144958920 | ||
035 | |a (DE-He213)s00408-023-00634-6-p | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q VZ |
245 | 1 | 0 | |a Abstracts from the 2023 American Cough Conference |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
500 | |a © Springer Science+Business Media, LLC, part of Springer Nature 2023 | ||
650 | 4 | |a Cough hypersensitivity syndrome | |
650 | 4 | |a Guaifenesin | |
650 | 4 | |a Camlipixant | |
650 | 4 | |a P2X3-receptor antagonist | |
650 | 4 | |a Tracheobronchomalacia | |
650 | 4 | |a Nalbuphine | |
650 | 4 | |a Cough monitoring | |
773 | 0 | 8 | |i Enthalten in |t Lung |d Springer US, 1976 |g 201(2023), Suppl 1 vom: Aug., Seite 1-6 |w (DE-627)129089729 |w (DE-600)6165-7 |w (DE-576)014424649 |x 0341-2040 |7 nnns |
773 | 1 | 8 | |g volume:201 |g year:2023 |g number:Suppl 1 |g month:08 |g pages:1-6 |
856 | 4 | 1 | |u https://doi.org/10.1007/s00408-023-00634-6 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_OLC | ||
912 | |a SSG-OLC-PHA | ||
912 | |a GBV_ILN_2018 | ||
951 | |a AR | ||
952 | |d 201 |j 2023 |e Suppl 1 |c 08 |h 1-6 |